Unitedhealthcare Partners With Independent Pharmacies for Telehealth and Testing
UnitedHealthcare, a unit of UnitedHealth Group Inc. (NYSE:UNH), has partnered with CPESN USA to launch a new care delivery model leveraging independent pharmacies for telehealth and testing services. This initiative aims to expand access to high-quality healthcare, especially in rural and underserved communities, by utilizing pharmacists as local access points. The program connects members with virtual care providers, offers point-of-care testing, and provides personalized health support to close care gaps and improve coordination.
CVS Health Raised Its 2026 Outlook 3 Times, but Not Its Dividend
CVS Health has maintained its dividend at $0.665 per share for 12 consecutive quarters despite raising its 2026 guidance three times, now expecting at least $8.20 adjusted EPS and $15.5 billion in operating cash flow. The company prioritizes share buybacks and a planned split into two public companies by the first half of 2028, with debt reduction achieved ahead of schedule. While financially capable of a dividend increase, strategic priorities currently take precedence, though Aetna's improved medical benefit ratio strengthens the long-term case.
Vaxcyte at jefferies global healthcare conference: adult vaccine path sharpens
Vaxcyte provided updates on its pneumococcal vaccine franchise at the Jefferies Global Healthcare Conference, highlighting positive Phase III adult study data for VAX-31 which met all endpoints and demonstrated non-inferiority to existing vaccines while offering broader coverage. The company aims for a biologics license application filing in the first half of 2028 and anticipates Phase II infant program data in the first half of 2027. Vaxcyte sees a substantial commercial opportunity in the adult market, which is expected to grow significantly, driven by broader serotype coverage.
Novo expands DTC program Novocare to support Wegovy users through holistic health journey
Novo Nordisk has rebranded its direct-to-patient pharmacy, NovoCare, to offer expanded services for Wegovy users, moving beyond just prescriptions to provide holistic health support. The program now includes treatment information, coaching, progress tracking, and partnerships with brands like Whoop and Stitch Fix to aid in lifestyle changes. NovoCare aims to be a comprehensive hub for patients and healthcare professionals, ensuring access to authentic medication and resources for navigating weight loss journeys.
With $477K in cash, DataMeds AI (MEDS) faces debt due within 12 months.
DataMeds AI (MEDS) reported a Q3 2026 net income of $10.5 million, largely due to a non-cash gain from debt extinguishment, but still faces substantial doubt about its ability to continue as a going concern. The company had only $476,598 in cash and $23.7 million in debt due within 12 months as of September 30, 2026, alongside a working-capital deficit of over $31 million. Management is pursuing various initiatives, including additional financing and liability reduction strategies, to address its liquidity challenges and Nasdaq listing compliance.
Marcus & Millichap Negotiates $5.5 Million Sale of Convenience Store in Southern Pennsylvania
Marcus & Millichap has successfully negotiated the $5.5 million sale of a newly developed Wawa convenience store and gas station in Greencastle, Pennsylvania. The 6,046-square-foot property, featuring 16 gas pumps, was sold to a Pennsylvania-based buyer. Scott Woodard, Derrick Dougherty, and Jacob Haslach represented the seller, a private investor, while Craig Dunkle procured the buyer.
The first 266 thousand Sanofi flu vaccines pass state control
The first 266,000 doses of Sanofi's flu vaccine have successfully passed state quality control in Ukraine. These vaccines are now being distributed to pharmacies and medical facilities across the country. The Ministry of Health confirmed that three batches of the vaccine received a positive assessment from Ukrpharmagency.
Insider Buying: Csquare (NYSE:CSQR) Director Acquires $172,400.00 in Stock
Csquare Director Philip Kelley recently purchased 10,000 shares of company stock for $172,400, effectively doubling his direct holdings to 20,000 shares. This transaction occurred despite Csquare missing its quarterly EPS consensus, though revenue did see a significant year-over-year increase. Analysts currently hold a "Moderate Buy" consensus rating for CSQR with an average price target of $28.78.
NextPlat Q3 2026 Earnings Call Transcript
NextPlat reported a significant improvement in Q3 2026 financial metrics, including reduced operating losses and increased margins, despite challenges in the healthcare sector. The company expanded its pharmacy footprint through strategic acquisitions and secured three new 340B contracts, while its e-commerce segment grew 3% year-over-year, aided by new partnerships like Decathlon. Management emphasized ongoing efforts to diversify and grow both healthcare and e-commerce segments through acquisitions and innovative service offerings.
MSCI Quarterly Review: Zhongji Innolight H-Shares Added to China Index; 38 Stocks Removed, Sands China Dropped from Hong Kong Index
MSCI announced its November 2026 quarterly index review results, effective November 30, with significant changes to its China and Hong Kong indexes. The MSCI China Index will add three constituents, including Zhongji Innolight H-shares, while removing 38 stocks. Sands China will be dropped from the MSCI Hong Kong Index.
CVS announces breakup, but its Ohio skeptics say it’s incomplete
CVS recently announced a corporate split into CVS Health and CVS Pharmacy, aiming for more focus and better customer experience, with completion expected in 2028. However, Ohio-based drug pricing expert Antonio Ciaccia views this as CVS divesting less profitable assets while retaining its most lucrative operations, including specialty drugs and its pharmacy benefit manager. Critics, including the American Economic Liberties Project, argue the split fails to address core conflicts of interest present when the same company owns both insurers and providers, which they believe drives up healthcare costs.
Zacks Research Upgrades DICK'S Sporting Goods (NYSE:DKS) to Hold
Zacks Research has upgraded DICK'S Sporting Goods (NYSE:DKS) from a "strong sell" to a "hold" rating. This upgrade comes as the retailer's latest quarterly earnings of $3.53 per share and revenue of $5.59 billion fell short of analysts' expectations, despite a significant year-over-year revenue increase. Analyst ratings are generally mixed, with an average price target of $166.55, and company insiders have recently purchased shares totaling approximately $5.59 million.
McKesson Credits AI, Automation Investments with Improving Distribution Performance
McKesson's CEO Brian Tyler attributes the company's improved distribution performance to years of strategic investments in technology, including AI, robotic process automation, and physical distribution. While McKesson has not quantified AI's direct financial contribution, it views large language models as integral to its broader strategy for efficiency, customer service, and profitability, rather than a standalone initiative. The company reported strong fiscal second-quarter revenue and net income, with growth in its pharmaceutical distribution and specialty health care businesses, supported by these ongoing technology and automation investments.
Remitly Global (NASDAQ:RELY) Director Joshua Hug Sells 5,500 Shares of Stock
Remitly Global director Joshua Hug sold 5,500 shares of the company's stock for $117,865, maintaining a significant stake afterward. This transaction was part of a pre-arranged trading plan, and comes as Remitly reported strong third-quarter earnings, beating revenue estimates and raising its full-year outlook. Analysts currently rate the stock as a "Moderate Buy" with an average price target of $27.78.
Synchrony’s Wenzel Talks Consumers, Workforce, AI
Synchrony CFO Brian Wenzel shared insights on the American consumer, emphasizing that their financial health is stronger than often reported, with payment patterns strengthening and high transaction volumes. He discussed the strategic integration of AI, focusing on reskilling employees and using AI for productivity gains rather than headcount reductions. Wenzel also highlighted Synchrony's successful hybrid work model and talent retention strategies, as well as its capital allocation priorities and partnership approach in the evolving commerce landscape.
EOG Resources, Inc. (NYSE:EOG) Increases Dividend to $1.10 Per Share
EOG Resources, Inc. has announced a 7.8% increase in its quarterly dividend to $1.10 per share, payable on January 29, 2027, to shareholders of record on January 15, 2027. The company has a consistent history of dividend increases, marking eight consecutive years. This announcement follows strong third-quarter results where EOG Resources surpassed analyst estimates for both earnings and revenue.
Inventiva among the biggest decliners in the SBF 120, down 4%
Inventiva, a biotech company specializing in fibrotic and metabolic diseases, saw its shares decline by 4.17% in the SBF 120 index. This drop placed it among the biggest decliners, erasing part of its recent rebound, and occurred amidst a broader market downturn influenced by Wall Street's performance. The company's financial outlook also notes a limited cash runway to Q2 2027 without additional financing, despite recent funding efforts.
FedEx Makes the Holidays Smarter with AI-Enabled Tools, Robotics, and Predictive Technology
FedEx is leveraging AI, robotics, and predictive technology to enhance its holiday season operations, offering customers improved tracking, clearer updates, and greater control over deliveries. New digital tools like FedEx Delivery Manager and Authenticated Delivery provide peace of mind, while Global Trade Navigator simplifies international shipping. Behind the scenes, AI-powered robots and meteorologists work to ensure packages move efficiently and safely, making the supply chain smarter and more reliable.
LTC Properties (NYSE:LTC) Now Covered by Analysts at Huntington
Huntington has initiated coverage on LTC Properties (NYSE:LTC) with a "strong-buy" rating, contributing to a "Moderate Buy" consensus rating and an average price target of $47.40 across analysts. The real estate investment trust recently exceeded quarterly earnings and revenue estimates, reporting core FFO of $0.71 per share and $114.08 million in revenue. Despite positive acquisition activity and strong Q3 results, the company's 2026 guidance was noted as less encouraging.
CVS Health Breakup Puts McKesson Stock And Pharmacy Rivals In Focus
The impending breakup of CVS Health into two separate companies is poised to reshape the retail drugstore landscape, creating new opportunities and risks for market participants. This article examines three stocks—Guardian Pharmacy Services (GRDN), Cardinal Health (CAH), and McKesson (MCK)—that are particularly exposed to this industry shift. The analysis delves into how the CVS split might affect their pricing power, margins, and earnings potential, especially as the focus shifts towards higher-value services and specialized pharmaceutical distribution.
CVS Health plans to split itself up. Here's why a breakup could make sense now
CVS Health announced plans to split into two publicly traded companies by the first half of 2028, separating its pharmacy business from its insurer, Aetna, and pharmacy benefit manager, Caremark. This move comes after a two-year turnaround in its retail pharmacy business, which analysts now deem strong enough to stand alone. The company had previously considered a breakup in 2024 but decided against it, with the current decision driven by increased profitability and improved performance across its units.
CVS Health Q3 2026 Earnings Call Transcript
CVS Health announced its plan to separate into two independent publicly traded companies: CVS Health (healthcare solutions) and CVS Pharmacy (retail and community healthcare). The company reported adjusted operating income of $4.2 billion and adjusted earnings per share of $2.09 for Q3 2026, raising full-year 2026 EPS guidance to at least $8.20 and projecting 2027 adjusted EPS of at least $8.65. This strategic move, taken from a position of financial strength, aims to increase focus, agility, and simplicity, with both new entities expected to maintain solid investment-grade credit ratings and tailored capital allocation strategies.
CVS Health announces it will split its pharmacy and insurance businesses
CVS Health announced its decision to split its pharmacy chain from its insurance business, creating two independent companies. This strategic reversal is expected to be completed by the first half of 2028 and aims to deliver more affordability, greater access, and a simpler experience in healthcare. David Joyner will lead the healthcare insurance company, while Prem Shah will head the CVS Pharmacy unit.
CVS to split off drugstore business in major breakup of healthcare giant; shares fall 10%
CVS Health announced plans to split into two separate public companies by the first half of 2028, reversing its $78 billion acquisition of Aetna in 2018. The move will separate CVS's 9,000 retail pharmacies from its insurance business and pharmacy benefit manager, Caremark. Following the announcement, CVS shares closed over 12% lower, despite the CEO stating the decision comes "out of a position of strength" due to business recovery.
CVS Health to break up into two companies, WSJ reports
CVS Health plans to split its $117 billion business into two publicly traded companies, separating its retail pharmacies from its Caremark pharmacy benefit management and Aetna insurance operations. One company will retain the CVS Health name, managing insurance, PBMs, primary care clinics, and specialty drugs, while the other, CVS Pharmacy, will encompass retail drugstores, mail-order pharmacy, and MinuteClinic. This strategic move aims to unlock shareholder value and address regulatory pressures, despite CEO David Joyner stating that regulatory issues were not the primary driver.
CVS Health to break up into two companies, WSJ reports
CVS Health plans to split its $117 billion business into two publicly traded companies, separating its retail pharmacies from its Caremark pharmacy benefit management operations and Aetna insurance company. One company will retain the CVS Health name, managing insurance and PBM units, primary care clinics, and specialty drugs, while the other, CVS Pharmacy, will encompass retail drugstores and MinuteClinic. This move comes amid increasing regulatory pressure and aims to potentially unlock greater shareholder value, although the CEO stated regulatory issues were not the primary driver.
Kontoor Brands Completes Sale of Lee to Authentic Brands Group
Kontoor Brands, Inc. has finalized the sale of its Lee business to Authentic Brands Group for up to $1 billion, including an upfront cash payment and a future earn-out opportunity. This strategic move allows Kontoor Brands to reduce debt, fund share repurchases, and concentrate on its remaining brands, Wrangler and Helly Hansen. Authentic Brands Group plans to leverage its global platform and licensing model with key operating partners to expand Lee's reach into new product categories and markets worldwide.
Syndigo Signs Multi-Year Strategic Partnership Agreement with Microsoft to Develop and Co-Sell AI-Powered Commerce Solutions
Syndigo has announced a multi-year strategic partnership with Microsoft to develop and co-sell AI-powered commerce solutions. This collaboration aims to integrate Microsoft Foundry, Agent 365, and other services into Syndigo's commerce data infrastructure, advancing their "Frontier Commerce" vision. The partnership will provide brands and retailers with a trusted product data foundation running on Microsoft Azure, enabling AI-powered workflows and connected experiences across all sales channels.
A pharmacy plans to start dispensing six compounded drugs in November. They are not FDA-approved.
DataMEDS AI announced that its subsidiary, Corexa Health, has secured a commercial supply agreement for six peptides (BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax) that were recommended by an FDA advisory committee. Corexa Pharmacy intends to begin dispensing these compliant compounded peptide prescriptions in November 2026. The company plans to use its Health Lives Here mobile application to collect and report safety data under an HHS enforcement discretion policy, emphasizing that these compounded drugs are not FDA-approved and have not been evaluated for safety or efficacy.
Is Cencora (COR) A Bargain As Oncology Expansion And Q4 Estimates Come Into Focus?
Cencora (COR) is drawing attention as analysts project strong Q4 earnings and revenue, driven by its oncology expansion, including the American Oncology Network acquisition. Despite a recent share price run, Cencora is considered 10% undervalued with a fair value estimate of $369.31, supported by its focus on high-margin specialty pharmaceuticals and active capital deployment through share repurchases. Investors are encouraged to assess the balance of Cencora's strong track record and new growth initiatives against potential risks like margin pressure from biosimilar volumes.
KT (KT) Expected to Post Earnings on Friday
KT (NYSE:KT) is scheduled to release its Q3 2026 earnings before market open on Friday, November 6th. Analysts are forecasting earnings of $0.574 per share on revenue of $5.12 billion. The company's shares opened at $17.17, close to their 52-week low, and analysts currently have a consensus "Hold" rating with an average price target of $23.08.
What Urban Edge Properties (UE) Said on Its Q3 Earnings Call
Urban Edge Properties (UE) reported strong third-quarter results, with funds from operations up 6% and same-property net operating income growing by 4.6%. The company raised its full-year FFO and same-property NOI guidance, while actively pursuing a capital recycling strategy, including the sale of a New Jersey property and strategic entry into the South Florida market with the acquisition of Regency Court. Additionally, Urban Edge highlighted robust leasing demand, significant redevelopment projects, and a strong balance sheet with ample liquidity.
MarketAxess (MKTX) Set to Release Quarterly Earnings on Friday
MarketAxess (MKTX) is scheduled to release its Q3 2026 earnings before market open on Friday, November 6th, with analysts expecting $1.95 EPS on $218.98 million in revenue. The company missed previous quarter estimates, reporting $1.86 EPS and $210.41 million in revenue, though revenue still grew by 0.8% year-over-year. MarketAxess also declared a quarterly dividend of $0.78 per share, representing a 1.9% annual yield, while Wall Street maintains a consensus "Hold" rating and an average price target of $159.44.
Five Below opens new Willow Street store in former Rite Aid space
Five Below has opened a new store in Willow Street, taking over a former Rite Aid space in the Kendig Square shopping center. The retailer sells a variety of items, mostly priced between $1 and $5, including decor, toys, candy, and sports items. This new location is one of four Five Below stores in Lancaster County, as the company continues its expansion across the U.S.
Teva Pharmaceutical appoints Dr. David J. Brailer to board of directors
Teva Pharmaceutical Industries Ltd. has announced the appointment of Dr. David J. Brailer to its board of directors, effective November 3, 2026. Dr. Brailer, currently Chairman and CEO of medem.ai and founder of Health Evolution, is deemed an independent director and will serve on the Human Resources and Compensation Committee and the Compliance Committee. He brings extensive experience from roles at The Cigna Group and other health technology companies.
Urban Edge Pays $90.3M for 140K-SF Boca Raton Retail Center
Urban Edge Properties has acquired Regency Court, a 140,000-square-foot grocery-anchored shopping center in Boca Raton, Florida, for $90.3 million from Invesco. The company underwrote the acquisition based on future rent-growth opportunities, as both anchor tenants, Publix and Walgreens, currently pay below-market rents with leases expiring in six years. Urban Edge anticipates an 8% to 9% unlevered internal rate of return from the property and plans to selectively pursue additional Florida opportunities.
Travelan outsells Imodium in pharmacies as Immuron's Australian sales climb
Immuron's travellers' diarrhoea tablet, Travelan, has surpassed Imodium in Australian pharmacy sales over the last 13 weeks, driven by a successful brand relaunch that boosted local sales by 14 percent in the September quarter. The company reported unaudited global sales of $2.2 million for Q1 FY27, with Australia contributing $1.8 million, while sales in the US declined and Canadian sales saw significant growth. Immuron expects improved US performance in the next quarter due to upcoming sales events and replenished inventory.
Marzetti hires president for retail business
The Marzetti Co. has appointed Mark Christenson as president of its retail business, where he will oversee sales, marketing, and innovation for the company's retail brands. Christenson previously served as chief revenue officer at Wingstop Restaurants Inc. and spent over 20 years at Procter & Gamble Co. Marzetti also announced Rob Reinerman as group vice president of brand and innovation and Rene Luichinger as chief customer officer in other organizational changes to strengthen its retail segment.
Immuron continued quarterly sales growth
Immuron Limited (ASX: IMC; NASDAQ: IMRN) announced double-digit sales growth for the quarter ending September 30, 2026, driven by a 14% increase in Australian Travelan® sales following a brand re-launch. Canadian Travelan® sales surged by 286% due to increased brand awareness, while US sales saw a 19% decrease but expect a positive outlook for the next quarter with upcoming Amazon Prime days and holiday sales events. The company also continues to expand market penetration for PROIBS® in Australia.
Physician's Choice expands retail footprint into GNC, Meijer and Kroger
Physician's Choice, a leading probiotic brand, has significantly expanded its retail presence by launching its gut health products in nearly 2,900 GNC, Meijer, and Kroger stores nationwide. This expansion makes its science-backed probiotics, digestive enzymes, and fiber supplements more accessible to consumers, with products ranging from $20.99 to $29.99. The rollout includes dedicated in-store promotions to support New Year wellness resolutions.
How is P&G’s CEO getting inflation-weary shoppers to pay more? It starts with cashmere-like diapers
Procter & Gamble's new CEO, Shailesh Jejurikar, is driving organic sales growth by employing a dual strategy: offering lower prices and new pack sizes for budget-conscious consumers, while introducing premium, innovative products like "cashmere-like" Pampers Amore diapers for those willing to pay more. This approach helped P&G achieve its best quarterly organic sales growth in nearly three years, reassuring investors amidst a challenging inflationary environment. The company's focus on superior innovation and targeted communication aims to maintain market share and pricing power, although the long-term willingness of shoppers to pay premium prices remains a question.
Blood pressure medication recalled due to potential superpotent drug
Viatris Inc. has voluntarily recalled over 21,000 bottles of its combination telmisartan and amlodipine blood pressure medication due to a potential for superpotent telmisartan. The FDA has categorized this as a class III recall, meaning use of the drug is unlikely to cause serious health consequences. Patients are advised to consult their doctors or pharmacists before discontinuing the medication.
How Investors Are Reacting To Centene (CNC) Ahead Of Earnings Report
Centene's Ambetter Health unit has announced its 2027 Marketplace lineup, which includes new chronic condition-specific Premier plans and expanded telehealth access. This strategic move aims to improve clinical workflow efficiency and influence Centene’s operating costs, though near-term earnings might not be immediately affected. Analysts project a revenue increase of 4.5% annually over the next three years, with a shift from a current loss to a 1.5% profit margin by 2029, suggesting a significant turnaround in profitability.
Alignment Health Adds New Medicare Advantage Plan in Pima County, Increasing Access and Choice for Arizona Seniors
Alignment Health Plan announced a new Medicare Advantage plan for Pima County, Arizona, starting January 1, 2027, aiming to provide seniors with low-cost coverage, access to local providers, and bilingual support. This addition, Alignment Health ONE (HMO), strengthens the company's Arizona portfolio to seven plans, serving nearly 1.1 million Medicare beneficiaries across Maricopa, Pima, and Santa Cruz counties. The plans offer diverse options, including specialized support for chronic conditions and benefits like grocery allowances and $0 copays on many prescribed medications.
Cencora: Doubles Down on Oncology With AON Acquisition; Fair Value Estimate Maintained
Cencora announced its acquisition of American Oncology Network (AON), valuing the target at $2.4 billion. Cencora, which already holds a 4% equity interest in AON, will pay $1.7 billion for 71% of AON if shareholders participate in an equity rollover. Morningstar is maintaining its fair value estimate for Cencora following this strategic move to strengthen its oncology focus.
Workhorse Partners with Tristan Fleet Management to Sell and Service All-electric W56 Step Vans in Canada
Workhorse Group, Inc. has announced a new dealer agreement with Tristan Fleet Management Inc. to sell and service its W56 electric step vans in Canada. This partnership marks Workhorse's first Canadian dealer, expanding on its five years of selling electric step vans in the country, notably through Purolator. Tristan will offer various W56 models with different battery and cargo configurations, leveraging its extensive network and service capabilities to support Workhorse's growth in the Canadian market.
Crossmark Global Holdings Inc. Buys 44,828 Shares of CVS Health Corporation $CVS
Crossmark Global Holdings Inc. increased its stake in CVS Health Corporation by 11.3% in the third quarter, purchasing an additional 44,828 shares. This brings their total holdings to 440,645 shares, valued at approximately $37.8 million. Other institutional investors also added to their positions, reflecting continued confidence in CVS Health, which reported strong quarterly results and a "Moderate Buy" consensus from analysts.
FitLife Brands at LD Micro main event: growth reset, margin push
FitLife Brands (FTLF) presented at the LD Micro 20th Annual Main Event Conference, detailing its transformation from near-bankruptcy in 2018 to a multi-brand nutrition platform with over $100 million in revenue. The company is now focused on restoring organic growth and improving gross margins, addressing challenges like Amazon algorithm changes, retail weakness, and declining product categories, while management expressed confidence in a potential re-rating of the stock's valuation.
Unilever to sell Welly bandage brand to Forward Consumer Partners
Unilever announced it will sell its Welly Health PBC bandage brand to private-equity firm Forward Consumer Partners. The financial terms of the sale were not disclosed. This move aligns with Unilever's strategy to focus on beauty and well-being brands, and Welly co-founder Eric Ryan is expected to return as an adviser.
Analysts cite USD 67.67 target for Prestige Consumer Healthcare stock
Analysts are setting a consensus price target of USD 67.67 for Prestige Consumer Healthcare (PBH) stock, significantly higher than its recent trading price of USD 49.92. The company reported first-quarter fiscal 2027 revenue of USD 265.71 million and adjusted EPS of USD 0.98. Investors are awaiting the upcoming second-quarter results scheduled for November 5, 2026, which will provide further insight into the company's financial trajectory.